19 Kasım 2026, Perşembe · 15:20 Piyasalar Açık
borsapanel.com Borsanın nabzı, tek panelde.
Abone Ol

Protagonist (PTGX), Blockbuster Statüsüne Yakın İki Uyuşturucu Olarak Kara Dönüşüyor

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

Maham Fatima

Sun, September 6, 2026 at 3:55 PM GMT+3 4 min read

On August 5, Protagonist Therapeutics (NASDAQ:PTGX) reported second-quarter 2026 results that flipped the company from red ink to a $162.8 million profit, or $2.29 per diluted share, compared with a $34.8 million loss a year earlier. The swing came as the company banked payments tied to two drugs moving from the lab bench to the pharmacy counter: ICOTYDE, an oral psoriasis treatment, and rusfertide, an injectable now awaiting an FDA decision. Cash and marketable securities climbed to $849.5 million. Here's what's fueling the optimism, and what could complicate it.

Protagonist (PTGX) Swings To A Profit As Two Drugs Near Blockbuster Status

Two Shots At Blockbuster Status

The quarter marked the first full three months of commercial sales for ICOTYDE, which won FDA approval on March 18 for moderate-to-severe plaque psoriasis in patients 12 and older weighing at least 40 kg. That approval triggered a $50 million milestone payment and made ICOTYDE, according to the company, the first and only FDA-approved targeted oral peptide for the condition. Protagonist can still collect up to $580 million more in milestones from partner Johnson & Johnson, plus royalties that average around 7.25 percent at $4 billion in annual sales.

Rusfertide carries even more weight. Its new drug application sits under Priority Review with a PDUFA goal date in August, backed by Breakthrough Therapy, Orphan Drug, and Fast Track designations for polycythemia vera. Partner Takeda already paid Protagonist $200 million on an opt-out election in April, with another $200 million and a $75 million approval milestone still due, on top of royalties that can reach 29 percent of sales above $1.5 billion. Behind both drugs, PN-881, an oral IL-17 antagonist, is heading into a Phase 2b psoriasis program in early 2027 after Phase 1 data showed drug levels beating their pharmacokinetic targets, and a Phase 1 study just began for PN-477sc, an injectable obesity peptide.

One-Time Payment, Real Questions

Look closer at that $213.5 million in license and collaboration revenue, and $192.4 million of it traces to the proportional recognition of Takeda's initial opt-out payment, not repeatable product sales. A year earlier, the same line item was just $5.5 million, so the growth reflects a single deal event more than an operating business scaling up. And that opt-out itself cuts both ways: Protagonist gave up its right to develop and commercialize rusfertide on its own, trading full ownership for royalties and milestones that depend on Takeda's execution rather than Protagonist's.

Spending is also set to climb. Management expects research and development costs to increase significantly in the second half of 2026 versus the first half, driven by the new PN-881 Phase 2b program, manufacturing investments, and added headcount. General and administrative costs are rising too, largely on stock-based compensation. And rusfertide's fate still hinges on an FDA decision that hasn't happened yet, priority review or not.

What Wall Street Is Pricing In

Hedge fund ownership ticked up from 42 funds to 43 last quarter, a modest gain rather than a rush in. Short interest sits at 13.99 percent of the float, a heavy load that signals real organized skepticism even as funds add positions. The stock trades at a forward P/E of 36.90 as of September 4, pricing in substantial earnings growth ahead. That combination suggests that the market hasn't fully settled on which story wins.

Two Bets Still Playing Out

The quarter's profit came largely from a deal payment, not proven commercial demand, which leaves the real test still ahead. For the bull case to hold, ICOTYDE's early adoption needs to keep building and rusfertide needs to clear its August PDUFA date. For the bear case to hold, rising R&D and G&A spending needs to outpace the royalty income trickling in from partners who now control both drugs' commercial futures.

While we acknowledge the potential of PTGX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.

Disclosure: None. Follow Insider Monkey on Google News.

Kaynak: Yahoo Finance
İlgili Haberler
Global Fed officials expect more rate hikes, worry about AI impact on inflation, minutes show CNBC Finance · 16 saat önce Global Teknolojik kesintiler insanların panikle alışveriş yapmasına neden oluyor. Costco bundan faydalanıyor CNBC Finance · 20 saat önce Global Fed'den Waller, merkez bankasının yarım puanlık faiz artırımıyla "insanları şok etmesi" gerekebileceğini söylüyor CNBC Finance · 23 saat önce Global Putin says EU is losing industry, falling behind competition ahead of meeting with Trump, Xi CNBC Finance · 1 gün önce Global "Breaking Bad" dizisinin yıldızı Dean Norris, boşanma sürecindeyken 4,5 hektarlık Kaliforniya'daki mülkünü 3,2 milyon dolara satıyor MarketWatch Top · 2 gün önce

Yorumlar (0)

Giriş yaparak yorum yazabilirsin.

İlk yorumu sen yaz.